Vaxxas and CEPI Advance US$4.8 million (AU$7.2 million) Program for Needle-Free Thermostable mRNA Vaccines
Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that CEPI, the Coalition for Epidemic Preparedness ...
Manufacturers' Monthly6h
Vaxxas and CEPI advance needle-free mRNA vaccines
Vaxxas has announced that the CEPI, has approved the progression of a $7.2 million program to develop heat-stable, ...